PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Anemia Aplástica, Mielodisplasia e Neutropenias Constitucionais Anemia Aplástica, Mielodisplasia e Neutropenias Constitucionais Clin Oncol. 2000;18(16):3038-51. 21. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328(18):1323-32. 22. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter- observer variability study. Br J Cancer. 1993;67(4):773-5. 23. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55. 24. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94(5):712-9. Epub 2009 Mar 31. 25. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826-31. 26. Capsoni F, Sarzi-Puttini P, Zanella A. Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005;7(5):208-14. Epub 2005 Aug 31. 27. Zeidler C, Welte K. Hematopoietic growth factors for the treatment of inherited cytopenias. Semin Hematol. 2007;44(3):133-7. 28. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol. 2002;39(2):89-94. 29. Carlsson G, Fasth A. Infantile genetic agranulocytosis, morbus Kostmann: presentation of six cases from the original “Kostmann family” and a review. Acta Paediatr. 2001;90(7):757-64. 30. Bernini JC, Wooley R, Buchanan GR. Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia. J Pediatr. 1996;129(4):551-8. 31. Lacerda JF, da Costa FL, Pereira AM, Príncipe F, Teixeira A, Parreira A, et al. [Use of granulocyte growth factors: recommendations of the Portuguese Society of Hematology]. Acta Med Port. 2008;21(5):412-26. Epub 2009 Jan 16. 32. Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92(1):68-75. 33. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonaldA, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106(3):803-11. Epub 2005Apr 19. 34. Marsh JC, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol. 2007;44(3):138-47. 35. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990;76(1):36-43. 36. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-205. Epub 2006 May 8. 37. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987;317(25):1545-52. 38. Sanz GF, Sanz MA, Vallespi T. Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. Hematol Cell Ther. 1997;39(6):277-94. 39. Ganser A, Völkers B, Greher J, Ottmann OG, Walther F, Becher R, et al. Recombinant human granulocyte- macrophage colony-stimulating factor in patients with myelodysplastic syndromes – a phase I/II trial. Blood. 1989;73(1):31-7. 40. Velloso ERP. Fatores de crescimento hemopoéticos nas síndromes mielodisplásicas. Rev Bras Hematol Hemoter. 2006;28(3):210-2. 41. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and quality- of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104(2):321-7. Epub 2004 Mar 30. 42. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 45